Added to YB: 2025-07-21
Pitch date: 2025-07-18
VCEL [bullish]
Vericel Corporation
+2.9%
current return
Author Info
No bio for this author
Company Info
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.
Market Cap
$2.0B
Pitch Price
$35.51
Price Target
59.00 (+61%)
Dividend
N/A
EV/EBITDA
67.92
P/E
161.63
EV/Sales
7.65
Sector
Biotechnology
Category
growth
Vericel Corporation (VCEL): An Analysis of a High-Growth Regenerative Medicine Leader at its Profitability Inflection Point
VCEL BUY: High-growth regenerative med leader w/ newly profitable inflection (net income $10.4M in 2024 vs -$3.2M 2023). MACI Arthro & NexoBrid launches driving sustained 20%+ rev growth in large TAMs. Zero debt, $167M cash, expanding margins (78% gross in Q4). DCF: $62.50, 21.5% 5-yr IRR. PT: $59 (48% upside).
Read full article (16 min)